ICD-10 Coding for PSA Follow-up with History of Prostate Issues
For a patient with prior prostate issues whose PSA decreased from 7-8 ng/mL to under 2 ng/mL, use Z12.5 (Encounter for screening for malignant neoplasm of prostate) as the primary code if this is routine surveillance, or Z85.46 (Personal history of malignant neoplasm of prostate) if the patient had prior prostate cancer treatment.
Coding Algorithm Based on Clinical Context
If Patient Had Prior Prostate Cancer (Treated):
- Primary code: Z85.46 (Personal history of malignant neoplasm of prostate)
- Secondary code: Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm)
- This applies when monitoring for recurrence after treatment (surgery, radiation, etc.)
If Patient Had Elevated PSA or Benign Prostate Issues (No Cancer Diagnosis):
- Primary code: Z12.5 (Encounter for screening for malignant neoplasm of prostate)
- Secondary code: N40.0-N40.3 (Benign prostatic hyperplasia) if BPH is documented
- Or R97.20 (Elevated prostate specific antigen) if documenting the history of prior elevation
If Currently Monitoring Active Surveillance:
- Primary code: C61 (Malignant neoplasm of prostate) - if cancer is present but untreated
- Secondary code: Z08 for surveillance visits
Clinical Context from Guidelines
The dramatic PSA decrease from 7-8 ng/mL to under 2 ng/mL is clinically significant. According to guidelines, men with PSA below 2.6 ng/mL have approximately 10% risk of cancer recurrence within 10 years 1. This favorable decrease suggests either:
- Successful treatment response (if cancer was treated)
- Resolution of benign prostatic inflammation
- Effect of 5-alpha reductase inhibitors (finasteride/dutasteride)
For ongoing monitoring, guidelines recommend PSA testing every 2 years when PSA is below 2.5 ng/mL 2, 3, 4, 5. The current PSA under 2 ng/mL places this patient in a lower-risk category for both cancer detection and recurrence.
Common Coding Pitfalls to Avoid
- Don't use R97.20 (Elevated PSA) as primary code when PSA is now normal - this describes current elevation, not history
- Don't use Z12.5 if patient has active cancer diagnosis - use C61 instead
- Always document whether "prostate issues" means prior cancer, BPH, prostatitis, or just PSA elevation - this determines correct coding
- If patient is on finasteride/dutasteride, note this - these medications reduce PSA by approximately 50% and affect interpretation 6
The specific ICD-10 code depends entirely on whether the "prostate issue" was cancer, benign disease, or simply PSA elevation. Request clarification from the provider if documentation is unclear, as this affects both coding accuracy and appropriate follow-up intervals per guidelines 4, 5.